Jeffrey A. Schneider

Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer

Jeffrey A. Schneider, Timothy W. Craven, Amanda C. Kasper et al. · Nature Communications · 2018 · 89 citations · Full text

Drug Target, Engineering, Peptoid-peptide Macrocycles +18

Manganese-induced oxidative DNA damage in neuronal SH-SY5Y cells: Attenuation of thymine base lesions by glutathione and N-acetylcysteine

Adrienne P. Stephenson, Jeffrey A. Schneider, Bryant C. Nelson et al. · Toxicology Letters · 2013 · 86 citations · Full text

Thymine Base Lesions, Dna Damage, Biochemistry +10

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

Metabolism of cadmium, zinc and copper in the rat kidney: the role of metallothionein and other binding sites.

David H. Petering, Jay Loftsgaarden, Jeffrey A. Schneider et al. · Environmental Health Perspectives · 1984 · 61 citations · Full text

Nutrition, Metal Contamination, Renal Inflammation +20

Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer

David R. Wise, Jeffrey A. Schneider, Joshua Armenia et al. · JCO Precision Oncology · 2020 · 59 citations · Full text